

# MAPPING THE SURVIVORSHIP AND SECONDARY PREVENTION SERVICES AVAILABLE TO EUROPEAN PROFESSIONALS IN AYA CANCER CARE

D. Stark<sup>1</sup>, E. Saloustros<sup>2</sup>, K. Michailidou<sup>3</sup>, S. Bielack<sup>4</sup>, L. Brugieres<sup>5</sup>, F.A. Peccatori<sup>6</sup>, S. Jezdic<sup>7</sup>, S. Essiaf<sup>8</sup>, J.-Y. Douillard<sup>7</sup>, G. Mountzios<sup>9</sup>

<sup>1</sup>Institute of Molecular Medicine, Leeds, UK; <sup>2</sup>Oncology Unit, General Hospital of Heraklion 'Venizelio', Heraklion, Crete, Greece; <sup>3</sup>Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; <sup>4</sup>Klinikum Stuttgart – Olgahospital, Stuttgart, Germany; <sup>5</sup>Gustave Roussy Cancer Campus, Villejuif, France; <sup>6</sup>Fertility & Procreation Unit, Gynecologic Oncology Department, European Institute of Oncology, Milan, Italy; <sup>7</sup>European Society for Medical Oncology, Viganello-Lugano, Switzerland; <sup>8</sup>European Society for Paediatric Oncology (SIOPE), Brussels, Belgium; <sup>9</sup>Department of Medical Oncology, 251 General Airforce Hospital, Athens, Greece

## INTRODUCTION

- Adolescents and young adults (AYA) are a distinct group at the interface between children's and adult's cancer patients.
- Increasing numbers of AYA are long-term cancer survivors, based on high cancer survival rate and low mortality from other diseases<sup>1</sup>.
- These factors result in several issues of specific or particular relevance to AYA, including<sup>2,3</sup>
  - the early effects of cancer and its treatment on fertility social wellbeing and mental health
  - the risks of late-occurring adverse events (i.e. cardiotoxicity, nephrotoxicity and second primary tumours)
- Recognizing the circumstances and needs of AYA living with and after cancer specifically, several reviews<sup>4,5</sup> of evidence, scientific data and priorities for AYA patients reflect increasing clinical community co-operation and research publication.

<sup>1</sup>Desandes E & Stark DP. Prog Tumor Res 2016;43:1-15; <sup>2</sup>Skinner R, et al. Lancet Oncol 2017;18:e75-90; <sup>3</sup>Keegan THM, et al. JAMA Oncol 2017;20; <sup>4</sup>Smith AW, et al. Cancer 2016;122:988-99; <sup>5</sup>Stark D et al. Eur J Cancer Care (Engl) 2016;25(3):419-27.

## ESMO/SIOPE SURVEY


- In 2016, the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) created a Joint Working Group on Cancer in AYA.
- Among its first projects, this group co-operated in an online professional survey to record the current status of AYA cancer care, aiming at identifying inequalities and focusing upon:
  - provision of educational content meeting professionals' interests and needs when managing AYA with cancer
  - widening and deepening of professional awareness of AYA with cancer in Europe
  - enactment of sensitive co-operative professional relations between medical and paediatric oncologists and other healthcare professionals involved in AYA cancer

## METHODS OF THE RESEARCH

- A link to a questionnaire was sent by e-mail in 2016 to all members of the ESMO and SIOPE and other AYA networks about:
  - availability of the services specialized in AYA patients
  - educational activities available to healthcare providers
  - maintaining the health of AYAs after cancer
  - means of raising awareness and improving care and outcome
- Data were analysed using  $\chi^2$  and Fisher's exact test.
- In this report we focus the display of results and the analysis upon:
  - late effects of cancer and its treatment
  - prevention of secondary malignant neoplasms
  - lifestyle to improve health


## RESULTS

Figure 1. Number of European respondents by region




**EE:** Belarus (n=2), Bulgaria (n=2), Czech Republic (n=3), Georgia (n=1), Hungary (n=3), Poland (n=5), Romania (n=8), Russia (n=5), Slovakia (n=3), Ukraine (n=3)  
**NE:** Denmark (n=5), Estonia (n=2), Finland (n=1), Iceland (n=1), Ireland (n=5), Latvia (n=2), Lithuania (n=4), Norway (n=1), Sweden (n=4), United Kingdom (n=24)  
**SE:** Albania (n=2), Andorra (n=1), Bosnia and Herzegovina (n=1), Croatia (n=6), Cyprus (n=3), Greece (n=27), Italy (n=15), Malta (n=2), Montenegro (n=1), Portugal (n=11), Serbia (n=3), Slovenia (n=2), Spain (n=9), (TFYR of Macedonia (n=2)  
**WE:** Austria (n=2), Belgium (n=13), France (n=26), Germany (n=37), Luxembourg (n=1), Netherlands (n=9), Switzerland (n=9)

Figure 2. Characteristics of the respondents



- Respondents were largely medical or paediatric oncologists, followed by other specialized physicians (Figure 2).
- 52% worked in general academic centres, 19% in specialised cancer hospitals and 11% in paediatric hospitals.
- 60% were trained to treat adult cancer patients, 25% paediatric patients and 15% both.


Figure 3. Access to specialist services for late effects



- The majority of professionals reported that 67% of their AYA patients had no access to specialist services to manage late effects.
- This trend was higher in SE and lower in NE (Figure 3).


- Nonetheless over 85% of professionals reported:
  - monitoring of cardiovascular disease risk factors (e.g. high-blood pressure, high cholesterol, obesity) after cardio-toxic treatments
  - advice on healthy body weight, alcohol consumption, diet, physical activity and safe sun exposure

Figure 4. Attitude of respondents towards tobacco use



- Smoking enquiry was reported as active by many respondents but simple action to modify behaviour about tobacco use is limited in AYA patients (Figure 4).


Figure 5. Evaluation of fertility



- Despite being a longstanding issue<sup>6</sup>, clinicians reported a very varied access of AYA patients to a fertility specialist across the four European regions (Figure 5; p<0.001).

<sup>6</sup>Chapman RM et al. Lancet. 1979;1(8111):285-9.

Figure 6. Specialised AYA care



- Respondents wanted education that ESMO and SIOPE should offer together, prioritizing cancer treatment services, basic science and clinical research (Figure 6).

- Awareness of research initiatives, clinical trials or studies focused upon the specific clinical, epidemiological or psycho-social features of AYA with cancer was only 11.8% and 10% for respondents in SE and EE, respectively, but 44% in EE and 54% NE.
- Access to an age-specialized nurse (10% and 32%), availability of specialised AYA education (7% and 14%) or support by young patient groups (34% and 48%) are alarmingly low in SE and EE, respectively.

## CONCLUSIONS

- This first survey of ESMO and SIOPE is a baseline to identify inequalities for AYA with cancer across Europe.
  - The lack of access to specialized AYA care is more profound in Southern and Eastern Europe
- There are significant limitations and inequalities in specialist services for AYA patient living after cancer.
  - Fertility services before and after cancer treatment are significantly unequal across Europe
  - Late effects services, prevention of second cancers and advice on lifestyle are very variable and widely need improvement
- ESMO and SIOPE are ideally placed to raise the profile of AYA cancer-related issues
  - increasing professional awareness of AYA cancer issues
  - providing further excellent educational material such as e-learning, specific guidelines, practical guides for clinicians, congress activities, educational lectures, interactive sessions
  - encouraging research
- Education for AYA professionals should be developed by ESMO and SIOPE in co-operation to reduce inequalities in AYA cancer outcomes.